Ardelyx presented data at the National Kidney Foundation's Spring Clinical Meetings showing that XPHOZAH (tenapanor) safely reduces serum phosphate without affecting other electrolytes in chronic kidney disease patients on dialysis. The analysis combined results from two clinical trials, NORMALIZE and OPTIMIZE, confirming no significant changes in nutrition, body mass, or blood pressure over extended use. This supports XPHOZAH's role as an effective add-on therapy for patients inadequately managed by phosphate binders. Ardelyx also hosted a peer exchange to discuss practical use and side effect management of XPHOZAH, which is taken twice daily and primarily causes mild to moderate diarrhea.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Viasat and BMW Group have successfully demonstrated the first integrated automotive satellite voice call, allowing drivers to make calls directly through the car's infotainment system even in areas without cellular coverage. This advancement, utilizi...
Iran has warned it will retaliate fiercely if the US targets its infrastructure, following President Trump's threat to strike Iranian power plants and bridges next week if negotiations fail. The US recently conducted airstrikes against Iranian milita...
Solana (SOL) maintains its price in the mid-$70 range, supported by several key developments. These include Circle's recent issuance of $500 million in USDC on the Solana network, increasing liquidity and transactional demand. Additionally, instituti...
